Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADA | P00813 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.39 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19038496 | 0.90 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6380801 | 0.83 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6388244 | 0.80 | ADORA2A (0.66) | ADORA2AADAHSPA5HSPA8RXFP1 | |
| SCHEMBL6426428 | 0.80 | ADORA2A (0.66) | ADORA2AADAHSPA5HSPA8RXFP1 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL12149452 | 0.79 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BADA | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL13772636 | 0.79 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL16174393 | 0.79 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2BADA | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL733423 | 0.79 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BADA | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL6422519 | 0.79 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BADA | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL14628545 | 0.79 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADORA3 170/4885ADORA1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.